Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non Operating Income (2020 - 2025)

Historic Other Non Operating Income for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$21000.0.

  • 4D Molecular Therapeutics' Other Non Operating Income fell 200000.0% to -$21000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$36000.0, marking a year-over-year increase of 4626.87%. This contributed to the annual value of -$77000.0 for FY2024, which is 5745.86% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Other Non Operating Income stood at -$21000.0 for Q3 2025, which was down 200000.0% from -$61000.0 recorded in Q2 2025.
  • 4D Molecular Therapeutics' Other Non Operating Income's 5-year high stood at $67000.0 during Q1 2025, with a 5-year trough of -$158000.0 in Q3 2023.
  • Its 5-year average for Other Non Operating Income is -$25117.6, with a median of -$13000.0 in 2021.
  • The largest annual percentage gain for 4D Molecular Therapeutics' Other Non Operating Income in the last 5 years was 77000.0% (2025), contrasted with its biggest fall of 200000.0% (2025).
  • 4D Molecular Therapeutics' Other Non Operating Income (Quarter) stood at -$7000.0 in 2021, then surged by 142.86% to $3000.0 in 2022, then plummeted by 466.67% to -$11000.0 in 2023, then plummeted by 90.91% to -$21000.0 in 2024, then changed by 0.0% to -$21000.0 in 2025.
  • Its last three reported values are -$21000.0 in Q3 2025, -$61000.0 for Q2 2025, and $67000.0 during Q1 2025.